Immunome, Inc. IMNM
18.41 USD -0.66 (-3.49%)
Nov 12, 2026, 1:04 PM EST
18.02 Day range 19.06
16.11 52-week range 30.06
- YTD
- -14.32%
- 1 year
- +5.59%
News
benzinga.com Immunome Analysts Cut Their Forecasts After Q3 Results Immunome Inc (NASDAQ:IMNM) on Monday posted a wider-than-expected loss for the third quarter.
benzinga.com Immunome Analysts Cut Their Forecasts After Q3 Results Immunome posted a wider Q3 loss than expected, shares fell 4.6%, and analysts cut price targets despite oncology pipeline progress.
benzinga.com Stifel Maintains Hold on Immunome, Lowers Price Target to $23 Stifel analyst Dara Azar maintains Immunome (NASDAQ:IMNM) with a Hold and lowers the price target from $24 to $23.
benzinga.com Piper Sandler Maintains Overweight on Immunome, Lowers Price Target to $30 Piper Sandler analyst Biren Amin maintains Immunome (NASDAQ:IMNM) with a Overweight and lowers the price target from $33 to $30.
businesswire.com Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced…
businesswire.com Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class cancer therapies,…
benzinga.com Immunome Says EMA Validates MAA For Varegacestat, Investigational, Oral, Once-Daily Gamma Secretase Inhibitor, For Treatment Of Adults With Desmoid Tumors The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements across the primary and all key secondary…
benzinga.com Wedbush Reiterates Outperform on Immunome, Maintains $35 Price Target Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $35 price target.- benzinga.com Immunome Showcases New Clinical Analyses Supporting Varegacestat's Profile In Desmoid Tumors At ESMO 2026 Rapid oral presentation highlights improvements in patient-reported symptom burden and physical function through week 48Four presentations build on the previously reported Phase 3 RINGSIDE…
benzinga.com Stifel Initiates Coverage On Immunome with Hold Rating, Announces Price Target of $24 Stifel analyst Dara Azar initiates coverage on Immunome (NASDAQ:IMNM) with a Hold rating and announces Price Target of $24.- benzinga.com Immunome Receives FDA Clearance For Its Investigational New Drug Application For IM-1340 To Treat Advanced Solid Tumors Immunome, Inc. (NASDAQ:IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S. Food and…
benzinga.com Alliance Global Partners Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $32 Alliance Global Partners analyst Matthew Venezia initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $32.- benzinga.com HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $40 price target.
benzinga.com ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braze and others also fell premarket.- benzinga.com Truist Securities Maintains Buy on Immunome, Raises Price Target to $38 Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price target from $37 to $38.
benzinga.com Wedbush Maintains Outperform on Immunome, Raises Price Target to $35 Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $31 to $35.- benzinga.com Immunome Q2 EPS $(0.65) Misses $(0.52) Estimate Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.52) by 25 percent. This is a 30 percent decrease over losses of $(0.50) per…
benzinga.com SpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures mixed, Dow up 100 points. SpaceX stock falls 10.3% after reporting strong Q2 revenue but a loss. Other stocks also decline.- benzinga.com Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.
benzinga.com Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review FDA accepts Immunome's varegacestat NDA for desmoid tumors, with an April 28, 2027, PDUFA date backed by positive Phase 3 data.- benzinga.com Immunome's New Drug Application For Desmoid Tumors Treatment Accepted By FDA, April 28, 2027 Assigned As Prescription Drug User Fee Act Target Action Date Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or…
- benzinga.com Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.
- benzinga.com Immunome Does First Participant In Its Phase 1 IM-1617 Study To Treat Solid Tumors Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the…
benzinga.com Truist Securities Maintains Buy on Immunome, Raises Price Target to $37 Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price target from $36 to $37.
benzinga.com Barclays Initiates Coverage On Immunome with Overweight Rating, Announces Price Target of $36 Barclays analyst Lukas Shumway initiates coverage on Immunome (NASDAQ:IMNM) with a Overweight rating and announces Price Target of $36.- benzinga.com HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $40 price target.
- benzinga.com Immunome Q1 EPS $(0.48) Beats $(0.57) Estimate Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.57) by 15.79 percent. This is a 7.69 percent increase over losses of $(0.52) per…
- benzinga.com Immunome Reveals Oral Presentation Of Phase 3 RINGSIDE Data At 2026 ASCO Annual Meeting Immunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its…
benzinga.com This Sezzle Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday 
benzinga.com The Insider Report: Batten Down the Hatches 
benzinga.com Kyverna Therapeutics, Immunome, Almonty Industries And Other Big Stocks Moving Higher On Monday 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com This Crocs Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday 
benzinga.com This GATX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday? In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding interest rate reductions.
- benzinga.com Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.
- benzinga.com Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue? The biotech sector has been surging in recent months, reawakening from a period of underperformance that followed the highs of 2021. David Prince, professional trader at T3 Trading Group, joined…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 807 companies reached new 52-week lows.
- benzinga.com 74 Biggest Movers From Yesterday Gainers T Stamp Inc. (NASDAQ: IDAI) shares surged 123.8% to close at $4.70 on Thursday. Trust Stamp reported the launch of its Biometric Multi-Factor Authentication (Biometric MFATM) solution.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
benzinga.com 68 Biggest Movers From Yesterday Gainers Casa Systems, Inc. (NASDAQ: CASA) shares surged 82.5% to close at $7.10 on Monday after the company announced a multi-year contract with Verizon to provide 5G core network functions.- benzinga.com 58 Biggest Movers From Friday Gainers BEST Inc. (NYSE: BEST) shares gained 73.6% to close at $1.00. DiDi Global Inc. (NYSE: DIDI) shares jumped 59.8% to settle at $4.09 on Friday.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 524 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 368 stocks hit new 52-week lows.